Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III, Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19

NCT05445934 is registered in ClinicalTrials.gov with Frontier Biotechnologies Inc. as lead sponsor.

NCT NCT05445934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05445934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III, Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19
Lead sponsor
Frontier Biotechnologies Inc.
Phase
Phase 2/3
Overall status
Unknown status
Start date
September 14, 2022
Completion date
December 31, 2023
Enrollment
1,188 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19